ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
Incyte/MSD's immunotherapy combo fails in Phase III
July 17, 2018A late stage trial testing Incyte’s epacadostat in combination with MSD’s Keytruda has failed to hit its primary targets in patients with unresectable or metastatic melanoma. -
Incyte, Merck Provide Update Study of Epacadostat in Combination with KEYTRUDA
April 09, 2018Incyte and Merck Announce the External Data Monitoring Committee (eDMC) to Review Key Phase 3 ECHO-301/KEYNOTE-252 Study Results for the Evaluation of Incyte's epacadostat in Combination with Merck's KEYTRUDA for Unresectable or Metastatic Melanoma Patien
Pharma Sources Insight January 2025
